Favicon of Flockhart CYP450 Table (Indiana University)

Flockhart CYP450 Table (Indiana University)

Clinically useful table of CYP450-mediated drug interactions maintained by Indiana University School of Medicine.

Can Flockhart CYP450 Table (Indiana University) be used with protected health information?

We have not verified a BAA statement from Flockhart CYP450 Table (Indiana University)

The vendor's own published pages do not state whether it signs a Business Associate Agreement. Unverified items are shown as Unknown on this profile, never guessed. Confirm with the vendor before using this product with protected health information.

Last verified March 23, 2026

Flockhart CYP450 Table (Indiana University) Overview

Clinical Pharmacology School of Medicine Drug Interactions Flockhart Table ™ This is dedicated to the memory of a pioneer in clinical pharmacology and pharmacogenetics and the creator of this table, Dr. David A. Flockhart, MD, PhD Drugs metabolized by the enzyme.

Color-Coded System: indicates the strength of evidence from literature evaluating the drug as a substrate for specific enzyme.

Strong Evidence: the enzyme is majorly responsible for drug metabolism. Moderate Evidence: the enzyme plays a significant but not exclusive role in drug metabolism or the supporting literature is not extensive. Weak Evidence: the enzyme plays minor role in drug metabolism or the available literature is limited. In-Vitro Evidence: evidence is based solely on in vitro studies. TBD: the strength of evidence is under review.

chlorpheniramine deutetrabenazine dexfenfluramine dextromethorphan methoxyamphetamine

Inhibitors compete with other drugs for a particular enzyme thus affecting the optimal level of metabolism of the substrate drug which in many cases affect the individual's response to that particular medication, e.g. making it ineffective.

A Strong inhibitor is one that causes a ≥ 5-fold increase in the plasma AUC values or more than 80% decrease in clearance. A Moderate inhibitor is one that causes a 2-fold to < 5-fold increase in the plasma AUC values or 50-80% decrease in clearance. A Weak inhibitor is one that causes a ≥ 1.25-fold but < 2-fold increase in the plasma AUC values or 20-50% decrease in clearance. In-Vitro Only In-Vitro Only evidence only. TBD Inhibitor strength level is under review.

Share:

Pricing

Contact vendor for pricing

Get a quote for Flockhart CYP450 Table (Indiana University)

Ad
Favicon

 

  
 

Similar to Flockhart CYP450 Table (Indiana University)

Favicon

 

  
  
Favicon

 

  
  
Favicon

 

  
  

Top Rated Flockhart CYP450 Table (Indiana University) Alternatives

Favicon

 

  
  
Favicon

 

  
  
Favicon

 

  
  
Favicon

 

  
  
Favicon

 

  
  
Favicon

 

  
  

Have you used Flockhart CYP450 Table (Indiana University)?

Share your experience to help healthcare professionals make better decisions.

Explore More